From Yahoo Finance: 2025-06-11 19:40:00

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) secures its composition of matter patent for Nuplazid, a medication for Parkinson’s disease psychosis, after U.S. Court of Appeals ruling. CEO Catherine Owen Adams confirms patent extended to 2030, bolstering market exclusivity against generic competition and legal stance against Aurobindo Pharma.

The U.S. FDA approved Nuplazid in 2016 for Parkinson’s disease-related delusions and hallucinations, reinforcing ACADIA Pharmaceuticals Inc.’s (NASDAQ:ACAD) position in a separate legal battle. The ruling ensures prolonged market exclusivity for Nuplazid, protecting its intellectual property portfolio.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) specializes in developing medications for central nervous system disorders. While ACAD shows investment potential, certain AI stocks may offer greater upside and lower risk. For an undervalued AI stock poised to benefit from Trump-era tariffs and onshoring trend, consider the best short-term AI stock.



Read more at Yahoo Finance: US Appeals Court Confirms Patent Validity of Acadia’s Parkinson’s Medication